Trial Profile

Long-term Study Evaluating the Effect of Givinostat in Patients With JAK2V617F Positive Chronic Myeloproliferative Neoplasms

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Givinostat (Primary)
Indications Myeloproliferative disorders
Focus Adverse reactions; Therapeutic Use
Sponsors Italfarmaco

Most Recent Events

28 Mar 2024 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
28 Mar 2024 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2026.
07 Oct 2022 This trial has been completed in Germany according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com